Watch our webinar titled “How Changes to the Patented Medicine Prices Review Board Could Affect Patients’ Access to Drugs”

This webinar introduces you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients. This webinar also provides you with the following information: Summary, analysis and next steps regarding proposed price regulation changes Patient perspectives on the proposed reforms Discussion on potential

New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer

KIRKLAND, QC, Sept. 20, 2017 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression, with no EGFR or ALK genomic tumour aberrations and no prior systemic chemotherapy treatment. A

First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza® (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement

This marks an important first step towards providing Canadian women with access to this treatment MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ – AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza® (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer.1 Lynparza is an oral, potent

Cancer-Associated Thrombosis: A Critical Gap in Cancer Care

“Cancer-associated thrombosis (CAT) is one of the most common yet preventable causes of death among cancer patients. With over 20,000 Canadians being diagnosed with cancer each year, knowing about causes, prevention, and treatment of CAT will be critical to the quality of life and long-term survival of these individuals. CAT refers to blood clots that can

Registration Now Open for the Second Annual Drug Pricing Policy Summit

On November 15-16, 2017 from 8:30 a.m. – 5:00 p.m., you are invited to join the Save Your Skin Foundation, the Canadian Cancer Survivor Network and the Schizophrenia Society of Ontario and other patient groups for the second annual Drug Pricing Policy Summit – Measuring Progress and Making Our Mark. This year’s Summit will build

Saskatchewan latest province to help protect boys from cancer with HPV vaccine

Grade 6 boys in Saskatchewan will now receive a vaccine to prevent some types of cancer. Starting this year 7,500 boys will be eligible to receive the human papillomavirus, or HPV, vaccine. “If you knew you could prevent cancer and your son or daughter develops that cancer, and they still might, but if you had

pCODR gives initial positive recommendation for Ovarian Cancer Drug

pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer. As part of their recommendation, pCODR stated that “Reimbursement should be for olaparib monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic as detected by approved testing) high grade serious epithelial ovarian, fallopian tube, or

Do You have Metastatic Prostate Cancer?

Bayer is conducting a research study in men with metastatic hormone-sensitive prostate cancer. The purpose of this study is to find out if the study drug is safe and effective at keeping prostate cancer under control or slowing the growth of tumors when given in addition to androgen deprivation therapy (ADT) and docetaxel chemotherapy. To